Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-10-31
2011-11-29
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S152100, C424S158100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388250
Reexamination Certificate
active
08067002
ABSTRACT:
The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly
patent: 5456909 (1995-10-01), Marsh et al.
patent: 5534615 (1996-07-01), Baker et al.
patent: 5624837 (1997-04-01), Fodor et al.
patent: 5627264 (1997-05-01), Fodor et al.
patent: 5679546 (1997-10-01), Ko et al.
patent: 5679564 (1997-10-01), Pace et al.
patent: 5851528 (1998-12-01), Ko et al.
patent: 5853722 (1998-12-01), Rollins et al.
patent: 5856297 (1999-01-01), Fearon et al.
patent: 5856300 (1999-01-01), Rittershaus et al.
patent: 5858969 (1999-01-01), Marsh et al.
patent: 5861156 (1999-01-01), George et al.
patent: 6333034 (2001-12-01), Gupta-Bansal et al.
patent: 6410708 (2002-06-01), Ashkenazi et al.
patent: 6472520 (2002-10-01), Fisher
patent: 6534058 (2003-03-01), Fung
patent: 6569992 (2003-05-01), LaFleur et al.
patent: 6642353 (2003-11-01), McConnell et al.
patent: 6838554 (2005-01-01), Ashkenazi et al.
patent: 6956107 (2005-10-01), Fung et al.
patent: 7112327 (2006-09-01), Fung
patent: 7192589 (2007-03-01), Ashkenazi et al.
patent: 7211400 (2007-05-01), Ashkenazi et al.
patent: 7419663 (2008-09-01), Ashkenazi et al.
patent: 7439331 (2008-10-01), Fung
patent: 7282565 (2010-08-01), Goddard et al.
patent: 2003/0129187 (2003-07-01), Fung et al.
patent: 2003/0207309 (2003-11-01), Hageman et al.
patent: 2004/0152105 (2004-08-01), Vogt et al.
patent: 2005/0191298 (2005-09-01), Bell et al.
patent: 2005/0197285 (2005-09-01), Rosen et al.
patent: 2005/0222027 (2005-10-01), Chiang et al.
patent: 2006/0067935 (2006-03-01), Ambati
patent: 2006/0233803 (2006-10-01), Ashkenazi et al.
patent: 2007/0190054 (2007-08-01), Ashkenazi et al.
patent: 2008/0193442 (2008-08-01), Fung et al.
patent: 2009/0181017 (2009-07-01), Hass et al.
patent: 2009/0214538 (2009-08-01), Fung et al.
patent: 2009/0269338 (2009-10-01), Huang et al.
patent: 2011/0123528 (2011-05-01), An et al.
patent: 0 239 400 (1994-03-01), None
patent: 95/29697 (1995-11-01), None
patent: WO 99/27098 (1999-03-01), None
patent: WO 99/40100 (1999-08-01), None
patent: WO 99/42133 (1999-08-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 00/12703 (2000-03-01), None
patent: WO 00/036102 (2000-06-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 00/53749 (2000-09-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/04311 (2001-01-01), None
patent: WO 01/36432 (2001-05-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 02/30985 (2002-04-01), None
patent: WO 2004/014953 (2004-02-01), None
patent: WO 2004/022594 (2004-03-01), None
patent: WO 2005/025509 (2005-03-01), None
patent: WO 2005/102387 (2005-11-01), None
patent: WO 2006/042329 (2006-04-01), None
patent: WO 2006/062716 (2006-06-01), None
patent: WO 2006/071856 (2006-07-01), None
patent: WO 2006/088950 (2006-08-01), None
patent: WO 2007/044668 (2007-04-01), None
patent: WO 2007/053447 (2007-05-01), None
patent: WO 2007/56227 (2007-05-01), None
patent: WO 2007/087384 (2007-08-01), None
patent: WO 2008/055206 (2008-05-01), None
patent: WO 2008/147883 (2008-12-01), None
patent: WO 2009/134711 (2009-11-01), None
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy”. Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992).
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins.” J. Mol. Biol., 196:901-917 (1987).
Evans et al., “Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector that Replicates in COS and 293 Cells,” J. Immunol., 184: 123-138 (1995).
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys”. J. Immunol., 147(4):1352-1959 (1991).
Harboe et al., “The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.” Clinical and Experimental Immunology, 138(3):439-446 (2004).
Haubenwallner et al., “A novel missense mutation in the gene for lipoprotein lipase resulting in a highly conservative amino acid substitution (Asp180→Glu) causes familial chylomicronemia (type I hyperlipoproteinemia)” Genomics, 18(2):392-396 (1993).
Huber-Lang et al., “Role of C5a in Multiorgan Failure During Sepsis” J. of Immunology, 166:1193-1198 (2001).
Jaffers et al., “Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression”. Transplantation 41(5):572-578 (1986).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse.” Nature, 321:522-525 (1986).
Junghans et al., “Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders”. Cancer Res. 50:1495-1502 (1990).
Khazaeli et al., “Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response”. J. Natl. Cancer Inst. 80:937-942 (1988).
Laubser et al., “Inhibition of Complement, Neutrophil, and Platelet Activation by an Anti-Factor D Antibody During Extracorporeal Circulation”, Presented at the Annual Meeting of American Society of Anestesiologists, San Francisco, California, Oct. 14-18, 2000 (Abstract A-657).
Miller et al., “Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma”. Blood, 62:988-995 (1983).
Mulligan et al., “Protective Effects of Soluble CR1 in Complement and Neutrophil-Medicated Tissue Injury”, J. Immunol., 148(5):1479-1485 (1992).
Narayana et al., “Structure of Human Factor D:A Complement System Protein at 20.degree. Resolution”, J. Mol. Biol., 235: 695-708 (1994).
Niemann et al., “The Use of Monoclonal Antibodies as Probes of the Three Dimensional Structure of Human Complement Factor D”, J. Immunol., 132(2): 809-815 (1984).
Ray et al., “Thrombin Receptor: A Novel Target for Antiplatelet Drug Development”, Thrombosis Research, 87(1): 37-50 (1997).
Riechmann et al., “Reshaping human antibodies for therapy”. Nature, 332:323-327 (1988).
Sears et al., “Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma”. J. Biol. Response Modifiers. 3:138-150 (1984).
Shawler et al., Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135(2):1530-1535 (1985).
Sim et al., “Serine Proteases of the Complement System”, Biochemical Society Transactions, vol. 28, Pt.5, pp. 545-550 (2000).
Sims et al., “A humanized CD18 antibody can block function without cell destruction”. J. Immunol., 151(4):2296-2308 (1993).
Ündar et al., “Novel Anti-Factor D Monoclonal Antibody Inhibits Complement, Neutrophil, and Platelet Activation in a Simulated Pediatric Cardiopulmonary Bypass Circuit”., Presented in the 46thAnnual Conference of the American Society for Artificial Internal Organs, New York, N.Y., Jun. 28-Jul. 1, 2000, (Abstract).
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity”. Science, 239:1534-1536 (1988).
Volanakis et al., “Complement Enzymes”, In:The Human Complement System in Health&Disease, Chapter 4, pp. 49-81, Eds., J. Volonakis & M. M. Frank, Published by Marcel Dekker, Inc. New York (1998).
Volanakis et al., “Complement Factor D, A Novel Serine Protease”, Protein Science, 5:553-564 (1996).
White et al., “Human
An Ling-Ling
Fung Sek Chung
Kelley Robert F.
Lowman Henry B.
Singh Sanjaya
Gambel Phillip
Genentech Inc.
Jones Day
LandOfFree
Humanized anti-factor D antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-factor D antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-factor D antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268874